tiprankstipranks
Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham
The Fly

Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham

Needham analyst Ami Fadia lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $19 from $22 and keeps a Buy rating on the shares. The shares “will be under significant pressure” following yesterday’s pre-announcement wherein Q4 Lumryz sales slightly missed consensus, and the 2025 sales outlook of $240M-$260M came in well below the consensus of $290M, the analyst tells investors in a research note. The firm cut estimates but continues to believe the stock is undervalued, even if Lumryz achieves half of management’s peak sales outlook of $1B. Needham still sees “meaningful value” at current Avadel share levels.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App